Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282399 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00282399: Clinical Trial Phase 1 study, sponsored by Eisai.
NCT00282399 is a Phase 1 study that was terminated before completion, run by Eisai. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282399, a Phase 1 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).
Interventions
- DRUG Subcutaneous Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Why NCT00282399 stopped before completion
NCT00282399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous Decitabine is the first listed.
NCT00282399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00282399 about?
NCT00282399 is a clinical study titled "A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome". The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT00282399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2006-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00282399?
The interventions under investigation include: Subcutaneous Decitabine (DRUG).
Who is sponsoring clinical trial NCT00282399?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00282399's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia